Introduction
Oncolytic viruses are selectively replicating agents that eliminate tumor cells while sparing normal neighboring cells and, unlike other anticancer agents, they can selfpropagate and thereby magnify the therapeutic dose in a tumor-dependent manner. 1 In addition, they have the ability to circulate within the body, making the treatment of both primary and metastatic lesions possible. However, to date, oncolytic viruses have yet to reach their full potential as an effective new class of anticancer agents. Although proven to be safe in numerous clinical trials, their overall effectiveness as a monotherapy has been disappointing. With only one oncolytic virus (H101) 2 approved as treatment for cancer, increasing the potency of these agents is necessary if they are to be considered as a viable treatment for cancer.
We have recently developed a novel, chimeric adenovirus-3 (Ad3)/Ad11p oncolytic virus, termed 'ColoAd1'. 1 This virus has been shown to have superior potency over its parental viruses in vitro (on a panel of tumor cell lines), ex vivo (on patient tumor explants) and in vivo (in a liver metastasis colon cancer model). Although ColoAd1 has shown a high degree of selectivity and safety in all studies that have been carried out to date, these are artificial systems that may not fully mimic the conditions in a cancer patient. Therefore, to ensure sufficient safety in the clinic, we have explored whether clinically approved antiviral agents that have been used as experimental treatments for Ad infections, ribovirin (RBV) and cidofovir (CDV), might serve as potential 'safety valves' for this virus treatment. In addition, the herpes simplex virus-thymidine kinase (HSV-TK) gene has been incorporated into the ColoAd1 viral genome to test whether the genetically engineered sensitivity to ganciclovir (GCV) might be an effective treatment in abrogating the viral infection.
Adenoviruses cause a number of clinical syndromes in healthy, immune-competent individuals that are usually mild and self-limiting. However, Ad infection has become increasingly recognized as an important pathogen in individuals with impaired immune systems, resulting in acute hemorrhagic cystitis and acute renal failure in infants, young children, and in immunocompromised patients. As such, a variety of clinically approved antivirals have been tested as potential treatments including GCV, RBV and, CDV 3, 4 and only two, RBV and CDV, have shown encouraging clinical activity. [3] [4] [5] RBV (1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a purine nucleoside analog that is converted to its triphosphate form by cellular enzymes and has shown activity against several different viruses. RBV has been shown in vitro to be highly effective against the group C Ad viruses but ineffective against the other Ad groups. 6, 7 As ColoAd1 is derived from two group B viruses, Ad11p and Ad3, it is predicted that ) were seeded in a 96-well format at a density determined for each tumor cell line to generate a confluent monolayer within 24 h (10K per well for HUVEC, 50K per well for HT-29s, 50K per well for SKOV3). These densely seeded cells were allowed to grow for 2 additional days before exposure to the test virus(es). Infections of both tumor and primary normal cells were carried out in quadruplicate. The adenovirus (Ad) serotype Ad3 (GB strain) was purchased from ATCC and Ad11p (Slobitski strain) was a kind gift from Dr William SM Wold at the St Louis University. Viral stocks were propagated on human embryonic kidney 293 cells (McMaster University, Hamilton, Ontario, Canada) and purified on CsCl gradients. 24, 25 The method used to quantitate and partially characterize viral particles is based on that of Shabram et al., 26 with the exception that the anion-exchange media TMAE Fractogel (EM Sciences, Gibbstown, NJ, USA) was used instead of Resource Q (GE Healthcare, Piscataway, NJ, USA). 27 Each virus was diluted into 100 ml of media to obtain a virus input equivalent to their predetermined IC 50 
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ColoAd1 and its parent viruses, Ad3 or Ad11p, should be refractory to RBV treatment. Complicating this, however, is the fact that RBV and CDV are nucleoside and nucleotide analogs, which inhibit viral DNA replication by targeting the viral DNA polymerase. As this protein is altered in ColoAd1, 1 the ability of these treatments to affect the viral replication of this virus may not be predictable. When we tested the activity of RBV to block viral replication and the spread on a colon cancer cell line (HT-29), an ovarian cancer cell line (SKOV-3) and on normal endothelial cells (HUVEC (human umbilical vein endothelial cell)), ColoAd1 and its parent viruses were sensitive to RBV at higher concentration (333 mM) in the HT-29 cancer cell line, ColoAd1 and Ad3 were sensitive to RBV on the SKOV-3 cancer cell line, but all viruses were relatively refractory to treatment in the normal endothelial cell line (Figures 1a-c) . This suggests that RBV would not be an effective safety valve for ColoAd1 in the clinical setting.
Cidofovir is a monophosphate nucleotide analog of cytosine that inhibits viral DNA polymerases and shows activity against multiple DNA viruses. In an in vitro Therapeutic interventions for ColoAd1 M Bauzon et al study comparing CDV with RBV, CDV anti-Ad activity was significantly better than that of RBV, 8 and similar observations on a limited set of clinical isolates have also been reported. [9] [10] [11] The antiviral activity of CDV to ColoAd1 was tested along with its parent viruses, Ad11p and Ad3 (Figures 2a-c) . This study shows that ColoAd1 is sensitive to CDV treatment in HT29, SKOV-3 and HUVEC cells, with nearly complete inhibition achieved in both tumor and normal cells, in contrast to the relatively weak antiviral activity observed in RBV (Figure 1) . Importantly, new lipid formulations of CDV exist with increased activity against Ad in vitro, including group B viruses, suggesting that these, too, may offer a potentially more effective alternative to the original CDV used in these studies. 12 An alternative to an approved antiviral for intervention in the clinical setting is to genetically engineer the virus to create sensitivity to an approved drug. In the case of an oncolytic virus, this can be accomplished by 'arming' the virus with a pro-drug-converting enzyme and administering an approved pro-drug. 13 The choice of incorporating the HSV-TK gene into the virus as a safety valve is based on several parameters. As shown earlier by others, 8 the HSV-TK gene, when incorporated and expressed from a replicating viral genome, can be a highly effective means for restricting virus replication and spread when the pro-drug GCV is administered to therapeutic levels. GCV and related agents, widely used in the treatment of HSV infection in humans, are poor substrates for the mammalian nucleoside monophosphate kinase, but can be converted 1000-fold more efficiently to the monophosphate by the HSV-TK gene. Subsequently, the GCV monophosphate can then be converted by cellular kinases first to GCV diphosphate and ultimately to the toxic GCV-triphosphate form. GCV triphosphate competes with deoxyguanosine triphosphate for incorporation into elongating DNA during cell division, causing the inhibition of the DNA polymerase and single strand breaks. 14, 15 The phosphorylation of the GCV pro-drug changes it from a form that freely passes through cell membranes, into a more hydrophilic molecule and thus, prevents it from penetrating the cell membrane, creating a dependence on gap junctions or, in fewer examples, other poorly described mechanisms for an effective bystander effect. 16 As most tumor tissues have been shown to downregulate the intercellular gap function communication, [17] [18] [19] [20] the active, toxic form of the pro-drug should be restricted to the infected cancer cell, creating the possibility of selectively eliminating only the virally infected cell and not the surrounding uninfected cells. These characteristics make the HSV-TK/GCV combination particularly suitable for the eradication of rapidly dividing tumor cells invading the non-proliferating tissue. Importantly, there is extensive clinical proof of concept for this approach as the administration of GCV at safe, well-tolerated doses to treat a virus containing the HSV-TK gene remains the primary treatment used for arresting the spread of HSV infections. To confirm this principle as a safety valve for ColoAd1, the HSV-TK gene was genetically engineered into ColoAd1 as described in the Material and methods section without the loss of lytic potential when compared with the parent ColoAd1 virus (Figure 3 ) and tested for sensitivity to GCV. As shown in Figures 4a and b , GCV is highly effective in arresting ColoAd1-mediated cell lysis, especially in the primary normal endothelial cells. Consequently, this suggests that genetically engineering sensitivity to GCV in ColoAd1 is a viable approach to arresting the viral infection.
It is important to note that the TK protein expression can also be exploited to image and track the activity of the virotherapy during the course of the virotherapy treatment. Positron emission tomography and single photon emission computed tomography, are both methods that are routinely used for the detection and monitoring of cancer and cancer therapies and are both viable means to detect the expression of the TK protein when an appropriate TK substrate is administered. 21, 22 Importantly, these substrates are selectively phosphorylated by the viral TK enzyme and, as outlined earlier, the phosphorylated form remains sequestered in the cell. The ability to monitor the activity of the biological agent in real time during treatment may be critical for translation of this therapy in the clinic. The ability to Therapeutic interventions for ColoAd1 M Bauzon et al detect the location, magnitude and duration of gene expression quantitatively and non-invasively creates an opportunity to track the virotherapy and its viability within the treated patient, thus allowing for more personalized treatment regimens based on need rather than on a pre-agreed-upon dosing regimen The ability to monitor the activity and intensity of the surrogate signal also creates an opportunity for clinicians to optimize combination therapies that are often used in the treatment of cancer. This is important as viral therapies have shown synergy with standard of care chemotherapy in the clinical setting 23 and, in combination with chemotherapy, represents the first approved virotherapy for the treatment of cancer. 2 The ability to develop effective treatments for cancer remains a significant challenge. Virotherapies represent a new frontier in the treatment of cancer and, as firstgeneration viruses have proven safe in the clinic, more potent agents are currently being developed. In this manuscript, we have outlined different approaches to ensure that these agents can be safely managed during the treatment of the patient. More specifically, we show that a novel, highly potent oncolytic virus, termed ColoAd1, can be controlled through outside intervention, either directly through a clinically approved antiviral drug or through genetically engineering drug sensitivity into the virus, further developing this agent as a viable next-generation virus for the treatment of human cancers. 
